Article
Epithelial-to-Mesenchymal Transition is a Cause of Both Intrinsic and Acquired Resistance to KRAS G12C Inhibitor in KRAS G12C-Mutant Non-Small Cell Lung Cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Nov 2020
Adachi Yuta, Ito Kentaro, Hayashi Yuko, Kimura Ryo, Tan Tuan Zea, Yamaguchi Rui, Ebi Hiromichi
Abstract excerpt
PURPOSE: KRAS is among the most commonly mutated oncogene in cancer including non-small cell lung cancer (NSCLC). In early clinical trials, inhibitors targeting G12C-mutant KRAS have achieved responses in some patients with NSCLC. Possible intrinsic and acquired resistance mechanisms to KRAS G12C inhibitors are not fully elucidated and will likely become important to identify. EXPERIMENTAL DESIGN: To identify...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.